Це відео не доступне.
Перепрошуємо.
Dr. Aman Chauhan discusses the DAREON™- 5: DLL-3 BiTE for Neuroendocrine Cancers
Вставка
- Опубліковано 6 бер 2024
- DAREON-5 is a phase 2 trial studying BI 764532, an antibody-like molecule (DLL3/CD3 bispecific) that may help the immune system fight cancer. This is a clinical trial for high grade neuroendocrine cancers. It is open to adults with small cell lung cancer and other neuroendocrine cancers including extra-pulmonary neuroendocrine carcinoma and large cell neuroendocrine carcinoma. The purpose of the study is to find a suitable dose of BI 764532. The study is sponsored by Boehringer Ingelheim.
For more information, visit www.lacnets.or....